On 31 May 2024, the European Medicines Agency (EMA) published the Committee for Medicinal Products for Human Use (CHMP) reflection paper on Creutzfeldt-Jakob disease (CJD) and plasma-derived and urine-derived medicinal products.
In a concerted effort to combat healthcare-associated infections (HAIs) and antimicrobial resistance (AMR), the European Centre for Disease Prevention and Control (ECDC) and the Belgian EU Presidency on 6-7 May co-hosted a conference at the national public health institute of Belgium, Sciensano, in Brussels.
A cross-border outbreak of Salmonella Mbandaka ST413 has been ongoing in the European Union/European Economic Area (EU/EEA) and the United Kingdom (UK) for over two years since September 2021, as detailed in an updated joint Rapid Outbreak Assessment by the European Centre for Disease Prevention and Control (ECDC) and the European Food Safety Authority (EFSA).
Resistance of Salmonella and Campylobacter bacteria to commonly used antimicrobials continues to be observed frequently in humans and animals, according to a report issued today by EFSA and ECDC.
Since the most recent ECDC rapid risk assessment in 2021, the number of EU/EEA countries reporting hypervirulent Klebsiella pneumoniae (hvKp) sequence type (ST) 23 has increased from four to ten and the number of cases reported to ECDC by the countries, increased from 12 to 143.
The food-borne infections listeriosis and shigatoxigenic Escherichia coli are increasing in the EU/EEA and were in 2022 at levels higher than before the COVID-19 pandemic.